Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome

Stephen J. Cavalieri, Seunghyug Kwon, Renuga Vivekanandan, Sumaya Ased, Cassara Carroll, Jennifer Anthone, D. Schmidt, M. Baysden, Christopher J. Destache

Research output: Contribution to journalArticle

Abstract

We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.

Original languageEnglish (US)
JournalDiagnostic Microbiology and Infectious Disease
DOIs
StatePublished - Jan 1 2019

Fingerprint

Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Hospitalization
Routine Diagnostic Tests
Length of Stay
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome. / Cavalieri, Stephen J.; Kwon, Seunghyug; Vivekanandan, Renuga; Ased, Sumaya; Carroll, Cassara; Anthone, Jennifer; Schmidt, D.; Baysden, M.; Destache, Christopher J.

In: Diagnostic Microbiology and Infectious Disease, 01.01.2019.

Research output: Contribution to journalArticle

Cavalieri, Stephen J. ; Kwon, Seunghyug ; Vivekanandan, Renuga ; Ased, Sumaya ; Carroll, Cassara ; Anthone, Jennifer ; Schmidt, D. ; Baysden, M. ; Destache, Christopher J. / Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome. In: Diagnostic Microbiology and Infectious Disease. 2019.
@article{6415ab6686e2461caabed3e7f414343b,
title = "Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome",
abstract = "We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.",
author = "Cavalieri, {Stephen J.} and Seunghyug Kwon and Renuga Vivekanandan and Sumaya Ased and Cassara Carroll and Jennifer Anthone and D. Schmidt and M. Baysden and Destache, {Christopher J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diagmicrobio.2019.05.020",
language = "English (US)",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome

AU - Cavalieri, Stephen J.

AU - Kwon, Seunghyug

AU - Vivekanandan, Renuga

AU - Ased, Sumaya

AU - Carroll, Cassara

AU - Anthone, Jennifer

AU - Schmidt, D.

AU - Baysden, M.

AU - Destache, Christopher J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.

AB - We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85068268847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068268847&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.05.020

DO - 10.1016/j.diagmicrobio.2019.05.020

M3 - Article

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

ER -